A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of Natalizumab on Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis, with Optional Open-Label Extension

Discontinued
Phase of Trial: Phase III

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms ASCEND; ASCEND in SPMS
  • Sponsors Biogen
  • Most Recent Events

    • 28 Oct 2017 Results of pooled data from four trial ( INFORMS, ASCEND, ORATORIO and EXPAND), were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Apr 2017 Results assessing long term efficacy of natalizumab in ASCEND extension study, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of post hoc analysis assessing sustained disability improvements over 2 years, presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top